Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
This small randomized trial including patients with non-diabetic nephropathy looked at the addition of dietary sodium restriction or angiotensin receptor blockade (or their combination), in patients receiving background treatment with angiotensin converting enzyme (ACE) inhibition at maximum dose. Dietary sodium restriction to a level recommended in guidelines was more effective than dual blockade for reduction of proteinuria and blood pressure. Hard clinical endpoints were not examined in this study.
- Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)
- Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease
- Fatal and Nonfatal Outcomes, Incidence of Hypertension, and Blood Pressure Changes in Relation to Urinary Sodium Excretion